Risk Factors in Severe Anaphylaxis: Which Matters the Most, Food or Cofactors?


Journal

Journal of investigational allergology & clinical immunology
ISSN: 1018-9068
Titre abrégé: J Investig Allergol Clin Immunol
Pays: Spain
ID NLM: 9107858

Informations de publication

Date de publication:
22 Jul 2022
Historique:
pubmed: 5 5 2021
medline: 26 7 2022
entrez: 4 5 2021
Statut: ppublish

Résumé

The prevalence of anaphylactic shock, the most severe manifestation of anaphylaxis, remains unknown. Risk factors and biomarkers have not been fully identified. Objective: To identify risk factors in patients who experience anaphylactic shock. Using lipid transfer protein (LTP) allergy as a model, we compared the characteristics of patients who developed anaphylaxis and anaphylactic shock. We recorded demographics, pollen sensitization, foods ingested up to 2 hours before onset of the reaction, and the presence of cofactors. Culprit foods were identified through a compatible clinical history and positive allergology work-up (skin prick test and/or sIgE). We evaluated 150 reactions in 55 patients with anaphylaxis (134 reactions) and 12 with anaphylactic shock (16 reactions). Patients in the anaphylaxis group experienced twice as many reactions (mean [SD], 2.4 [2.5] for anaphylaxis vs 1.3 [1.5] for anaphylactic shock; P<.02). No relationship was found between any food group and severity of the reaction. The most frequent food involved in both groups of patients was the combination of several plant-derived foods (plant food mix), followed by peach and nuts. Indeed, in the reactions caused by plant food mix, the presence of a cofactor was observed more often than in other food groups. On the other hand, cofactors were not present in peach- and nut-related reactions. Exercise was the most frequent cofactor in all groups. In our series, the severity of the reactions was not determined by the kind of food or presence of a cofactor. Anaphylactic shock seems to be an infrequent presentation that may be associated with other individual-related factors requiring further evaluation.

Sections du résumé

BACKGROUND AND OBJECTIVE UNASSIGNED
The prevalence of anaphylactic shock, the most severe manifestation of anaphylaxis, remains unknown. Risk factors and biomarkers have not been fully identified. Objective: To identify risk factors in patients who experience anaphylactic shock.
METHODS METHODS
Using lipid transfer protein (LTP) allergy as a model, we compared the characteristics of patients who developed anaphylaxis and anaphylactic shock. We recorded demographics, pollen sensitization, foods ingested up to 2 hours before onset of the reaction, and the presence of cofactors. Culprit foods were identified through a compatible clinical history and positive allergology work-up (skin prick test and/or sIgE).
RESULTS RESULTS
We evaluated 150 reactions in 55 patients with anaphylaxis (134 reactions) and 12 with anaphylactic shock (16 reactions). Patients in the anaphylaxis group experienced twice as many reactions (mean [SD], 2.4 [2.5] for anaphylaxis vs 1.3 [1.5] for anaphylactic shock; P<.02). No relationship was found between any food group and severity of the reaction. The most frequent food involved in both groups of patients was the combination of several plant-derived foods (plant food mix), followed by peach and nuts. Indeed, in the reactions caused by plant food mix, the presence of a cofactor was observed more often than in other food groups. On the other hand, cofactors were not present in peach- and nut-related reactions. Exercise was the most frequent cofactor in all groups.
CONCLUSION CONCLUSIONS
In our series, the severity of the reactions was not determined by the kind of food or presence of a cofactor. Anaphylactic shock seems to be an infrequent presentation that may be associated with other individual-related factors requiring further evaluation.

Identifiants

pubmed: 33944786
doi: 10.18176/jiaci.0698
doi:

Substances chimiques

Allergens 0
Antigens, Plant 0
Plant Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

282-290

Auteurs

R Casas-Saucedo (R)

FAllergy Section, Pneumology Department, Hospital Clinic, University of Barcelona, Barcelona, Spain.
IRCE - Institut d´Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
ARADyAL, Carlos III Health Institute.

C de la Cruz (C)

FAllergy Section, Pneumology Department, Hospital Clinic, University of Barcelona, Barcelona, Spain.

G Araujo-Sánchez (G)

FAllergy Section, Pneumology Department, Hospital Clinic, University of Barcelona, Barcelona, Spain.
IRCE - Institut d´Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
ARADyAL, Carlos III Health Institute.

S Gelis (S)

FAllergy Section, Pneumology Department, Hospital Clinic, University of Barcelona, Barcelona, Spain.
IRCE - Institut d´Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

T Jimenez (T)

IRCE - Institut d´Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Allergy Section, Alicante General University Hospital-ISABIAL, Alicante, Spain.

S Riggioni (S)

FAllergy Section, Pneumology Department, Hospital Clinic, University of Barcelona, Barcelona, Spain.

C San Bartolomé (C)

IRCE - Institut d´Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
ARADyAL, Carlos III Health Institute.
Immunology Department, Hospital Clinic, University of Barcelona, Barcelona, Spain.

M Pascal (M)

IRCE - Institut d´Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
ARADyAL, Carlos III Health Institute.
Immunology Department, Hospital Clinic, University of Barcelona, Barcelona, Spain.

J Bartra Tomás (J)

FAllergy Section, Pneumology Department, Hospital Clinic, University of Barcelona, Barcelona, Spain.
IRCE - Institut d´Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
ARADyAL, Carlos III Health Institute.

R Muñoz-Cano (R)

FAllergy Section, Pneumology Department, Hospital Clinic, University of Barcelona, Barcelona, Spain.
IRCE - Institut d´Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
ARADyAL, Carlos III Health Institute.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH